Insider Buy Fuels Hope for EyePoint Amid 58% Stock Slump

Insider Buying Spurs a Momentary Rally in a Slumping Stock

On 18 August 2026, Director and owner Zaderej Karen L. executed a purchase of 10,600 shares of EyePoint Pharmaceuticals at an average price of $4.93 per share, bringing her total holding to 49,100 shares. The transaction occurred against a backdrop of a steep 58 % decline in the share price over the previous week and a year‑over‑year loss exceeding 50 % of the company’s market value. Despite the recent price erosion, the trade was completed at roughly 12 % above the prevailing market close, suggesting a conviction that the stock is undervalued relative to its current fundamentals. Social‑media chatter about the trade surged more than fourfold, with a sentiment score of +21, indicating heightened investor attention.

What the Transaction Signals for Investors

Insider activity is frequently interpreted by market participants as an implicit endorsement of a company’s trajectory. Zaderej’s latest purchase aligns with a pattern of incremental acquisitions, most of which occurred while EyePoint’s stock traded between $5.50 and $6.00. Earlier trades in May and July 2025 also involved buying at a premium, implying that the director perceives forthcoming data from the Phase 3 LUCIA trial and a potential FDA filing as catalysts capable of generating substantial upside. Consequently, investors may need to re‑examine the current valuation narrative. The negative price‑to‑earnings ratio and the steep price decline could be overstated if the company’s pipeline gains traction.

A Profile of Zaderej Karen L.

Zaderej has been an active owner for over a year, accumulating roughly 49,000 shares through a series of purchases totaling about 45,000 shares. All her orders have been classified as “buy” transactions, with no record of sales, reflecting a long‑term holding perspective. The purchase prices have ranged from $5.00 to $6.00, aligning with the company’s recent trading range and suggesting comfort in investing at a discount to the 52‑week high. Additionally, Zaderej sold a block of restricted stock units in July 2025, likely to free up liquidity for further equity purchases. The consistency of her buying pattern, coupled with the premium paid in the latest transaction, signals confidence in EyePoint’s strategic direction.

Company‑Wide Insider Activity Adds Context

Other senior executives, including President & CEO Duker Jay S. and Chief Medical Officer Ribeiro Ramiro, have also been active in buying and selling. The CEO’s transactions range from modest purchases of a few thousand shares to large sell orders, reflecting a balanced approach. Ramiro’s activity largely consists of buying common stock at $8–$15, slightly above the market price, underscoring a belief in the company’s long‑term trajectory. This mixed activity indicates that while insiders remain cautiously optimistic, they are also mindful of the company’s current volatility.

Outlook for EyePoint

EyePoint’s Phase 3 data for DURAVYU, coupled with expected results from the LUCIA trial, could serve as a potential catalyst for a turnaround. A pending FDA New Drug Application could materially elevate the stock’s valuation. However, the company’s negative earnings and recent share‑price decline highlight the inherent risk of a biotech investment. Investors should weigh insider confidence against the company’s still‑uncertain regulatory path. If the new data confirm the Phase 3 findings, the stock could rebound sharply; if not, the current price may reflect a significant discount to a more realistic valuation.

In summary, Zaderej Karen L.’s latest purchase is a bullish signal amid a bearish market backdrop. It indicates that key insiders view EyePoint’s pipeline as a potential upside catalyst and invites investors to reconsider whether the current price represents a temporary setback or a long‑term undervaluation.